Tactile Systems Technology (TCMD) risk factors, FY2024 10-K

Risks Related to Our Business, Operations and Strategy

1. 01Changes to the level of Medicare coverage or coverage criteria for our products could have an adverse effect on our business and results of operations
2. 02If we are unable to achieve and maintain adequate levels of coverage or reimbursement for our products, our business and results of operations will be adversely affected
3. 03or limit their coverage or reimbursement in the future, our business and results of operations could be adversely affected
4. 04Our operating results are directly dependent upon the sales and marketing efforts of our employees and upon our relationships with our distributors and their sales and marketing efforts. If our direct sales force or our distributors fail to adequately promote, market and sell our products, our sales may suffer
5. 05We utilize third-party, single-source suppliers for some components and materials used in our products, and the loss of any of these suppliers could have an adverse impact on our business
6. 06We are increasingly dependent on sophisticated information technology and if we fail to effectively maintain or protect our information systems or data, including from cyber-attacks or data breaches, our business could be adversely affected
7. 07We cannot assure you that cyber-attacks or data breaches will not occur or that systems issues will not arise in the future. Any significant breakdown, intrusion, breach, interruption, corruption or destruction of these systems could have a material adverse effect on our business and reputation
8. 08Our long-term growth depends on awareness and adoption of our products
9. 09Our revenue is primarily generated from our lymphedema products and we are therefore highly dependent on these products
10. 10Current or worsening economic conditions, including inflation, rising interest rates or a recession, could adversely affect our business and financial condition
11. 11Our business, financial condition and results of operations may be negatively impacted by health epidemics or other outbreaks
12. 12Consolidation in the healthcare industry could lead to demands for price concessions, which may impact our ability to sell our products at prices necessary to support our current business strategies
13. 13Changes in government trade policies, including additional tariffs and the resulting consequences, may have a material adverse impact on our business and results of operations
14. 14Increases in our operating costs could have an adverse effect on our financial condition and results of operations
15. 15We compete and may compete in the future against other companies, some of which have longer operating histories, more established products or greater resources than we do, which may harm our business
16. 16Our long-term growth depends on our ability to develop and commercialize additional products
17. 17existing products. Further, we may expend financial, management and operational resources on products that we are not able to successfully commercialize
18. 18It is difficult to forecast future performance and our financial results may vary from forecasts and may fluctuate from quarter to quarter
19. 19If physicians fail to properly document medical records for patients using our products, our business could be adversely impacted
20. 20The size of the market for our products is an estimate, and may be smaller than we believe
21. 21We may be unable to manage our growth effectively
22. 22Our ability to maintain our competitive position depends on our ability to attract, integrate and retain key executives and highly qualified personnel
23. 23Changes in reimbursement coding could impair our ability to receive reimbursement for our products
24. 24If the quality of our products does not meet the expectations of physicians or patients, then our brand and reputation could suffer and our business could be adversely impacted
25. 25If our facilities are damaged or become inoperable, we will be unable to continue to research, develop, manufacture and commercialize our products and, as a result, there will be an adverse impact on our business until we are able to secure a new facility
26. 26We may be adversely affected by natural disasters and other catastrophic events, and by man-made problems such as terrorism or violence, that could disrupt our business operations
27. 27Acquisition activity involves substantial risks, and we may not be able to successfully integrate newly acquired companies or businesses
28. 28If we commercialize any products outside of the United States, a variety of risks associated with international operations could impact our strategy and adversely affect our future growth
29. 29Government Regulation, Compliance and Legal Risks
30. 30Violations of federal and state regulations can result in severe criminal, civil and administrative penalties and sanctions, including debarment, suspension or exclusion from Medicare, Medicaid and other government reimbursement programs, any of which would have a material adverse effect on our business
31. 31We are subject to significant regulation by numerous government agencies, including the FDA. We cannot market or commercially distribute our products without obtaining and maintaining necessary regulatory clearances or approvals
32. 32If we fail to obtain and maintain regulatory clearances or approvals our ability to sell our products and generate revenue will be materially harmed
33. 33Our products are currently made available to authorized users of the Department of Veterans Affairs Federal Supply Schedule and if we were no longer eligible to sell our products through such channel, our business may be adversely affected
34. 34If clinical studies of our future products do not produce results necessary to support regulatory clearance or approval in the United States or, with respect to our current or future products, elsewhere, we will be unable to expand the indications for or commercialize these products
35. 35The initiation and completion of any of these studies may be prevented, delayed, or halted for numerous reasons
36. 36If the third parties on which we rely to conduct our clinical trials and to assist us with pre-clinical development do not perform as contractually required or expected, we may not be able to obtain regulatory clearance or approval for or commercialize our products
37. 37If we fail to comply with state and federal fraud and abuse laws, including anti-kickback, false claims and anti-inducement laws, we could face substantial penalties and our business, operations and financial condition could be adversely affected
38. 38Failure to maintain the licenses and accreditations necessary to operate under our direct-to-patient and -provider model would adversely affect our business
39. 39If we modify our FDA cleared devices, we may need to seek additional clearances or approvals, which, if not granted, would prevent us from selling our modified products
40. 40Our products may cause or contribute to adverse medical events that we are required to report to the FDA, and if we fail to do so, we would be subject to sanctions that would materially harm our business
41. 41Our products may in the future be subject to product recalls. A recall of our products, either voluntarily or at the direction of the FDA or another governmental authority, or the discovery of serious safety issues with our products, could have a significant adverse impact on us
42. 42If we or our component manufacturers fail to comply with the FDA's Quality System Regulation, our manufacturing operations could be interrupted, and our product sales and operating results could suffer
43. 43Any of these sanctions could adversely affect our business, financial condition and results of operations
44. 44Future regulatory actions may adversely affect our ability to sell our products profitably
45. 45In the United States, the legislative landscape, particularly as it relates to healthcare regulation and reimbursement coverage, continues to evolve. In March 2010 the ACA was passed and substantially changed healthcare financing by both governmental and private insurers
46. 46While our products are not currently subject to the competitive bidding process under Medicare, if our products were to become subject to such process in the future, it could negatively affect our business and financial condition
47. 47We are subject to additional federal, state and foreign laws and regulations relating to our healthcare business; our failure to comply with those laws could have an adverse impact on our business
48. 48Failure to comply with regulations affecting the transmission, security and privacy of health information could result in significant penalties
49. 49In addition, the FDA has issued guidance to which we may be subject concerning data security for medical devices
50. 50Failure to comply with privacy and data security laws and regulations could subject us to substantial penalties and our business, operations and financial condition could be adversely affected
51. 51We face the risk of product liability claims that could be expensive, divert management's attention and harm our reputation and business. We may not be able to maintain adequate product liability insurance
52. 52Our employees, distributors, independent contractors, consultants, collaborators and suppliers may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading
53. 53We may be unable to obtain or maintain international regulatory registrations or approvals for our current or future products and indications, which could adversely impact our business
54. 54Our operations involve the use of hazardous and toxic materials, and we must comply with environmental, health and safety laws and regulations, which can be expensive, and could have an adverse impact on our business

Financial Condition, Credit and Tax Risks

1. 55If we fail to maintain proper and effective internal control over financial reporting, our ability to produce accurate and timely financial statements could be impaired, which could harm our operating results, investors' views of us and, as a result, the value of our common stock
2. 56information technology; implement additional financial and management controls, reporting systems and procedures; and hire additional accounting and finance staff
3. 57Our credit facility contains covenants that restrict our business and financing activities, and the property that secures our obligations under the credit facility may be subject to foreclosure
4. 58We may need substantial additional funding and may be unable to raise capital when needed, which could force us to delay or reduce our commercialization efforts or product development programs
5. 59We may be subject to liabilities related to state income, sales and use taxes, which could adversely affect our financial condition and results of operations and could decrease demand for our products

Risks Related to Our Intellectual Property

1. 60We may not be able to protect our intellectual property rights throughout the world
2. 61the United States. These products may compete with our products in jurisdictions where we do not have any issued patents, and our patent claims or other intellectual property rights may not be effective or sufficient to prevent them from so competing
3. 62The patent protection for our products may expire before we are able to maximize their commercial value, which may subject us to increased competition and reduce or eliminate our opportunity to generate product revenue
4. 63We may not identify relevant patents or may incorrectly interpret the relevance, scope or expiration of a patent, which may adversely affect our ability to develop and market our products
5. 64Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements
6. 65We may become involved in lawsuits to protect our patents or other intellectual property rights, which could be expensive, time-consuming and ultimately unsuccessful
7. 66Third-party claims of intellectual property infringement or misappropriation may adversely affect our business and could prevent us from developing or commercializing our products
8. 67Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products
9. 68addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained
10. 69Because of the expense and uncertainty of litigation, we may not be in a position to enforce our intellectual property rights against third parties
11. 70Intellectual property rights do not address all potential threats to our competitive advantage
12. 71Confidentiality agreements with employees and others may not adequately prevent disclosure of trade secrets and protect other proprietary information
13. 72We may need to license certain intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms
14. 73We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties
15. 74We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property
16. 75Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed
17. 76If our trademarks and trade names are not adequately protected, then we may not be able to build and maintain name recognition in our markets of interest and our business may be adversely affected

Risks Related to Ownership of Our Common Stock

1. 77The trading price of the shares of our common stock has been and could continue to be highly volatile, and purchasers of our common stock may not be able to resell their shares of our common stock at or above the price at which they purchased their shares and could incur substantial losses
2. 78Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management
3. 79If securities or industry analysts do not publish research, or publish inaccurate or unfavorable research, about our business, the price of our common stock and our trading volume could decline
4. 80Our amended and restated certificate of incorporation and amended and restated bylaws provide that we will indemnify our directors and officers, in each case to the fullest extent permitted by Delaware law